期刊文献+

持续低流量灌注对离体鼠心的保护作用 被引量:1

Cardioprotective effect of low flow perfusion on isolated rat hearts
原文传递
导出
摘要 目的 观察p53基因、干细胞因子受体(CD117)和白细胞分化抗原44变异体5(CD44v5)在胸腺上皮肿瘤组织中的表达,结合其WHO分型及Masaoka分期,探讨三者与其病理特征及预后的关系.方法 利用组织芯片技术,通过免疫组织化学法检测p53、CD117和CD44v5在104例不同类型及分期的胸腺上皮肿瘤、10例正常胸腺组织中的表达,将结果与肿瘤病理学特征及预后进行分析.结果 p53、CD117及CD44v5在胸腺上皮肿瘤中阳性表达率分别为38.2%、15.7%和57.8%,三者在在正常胸腺组织中无明显表达.p53、CD117和CD44v5在不同WHO分型间表达差异有统计学意义(P<0.05),p53和CD44v5在不同Masaoka分期间表达差异有统计学意义(P<0.05).CD117和CD44v5在胸腺癌中显著高表达,阳性表达率分别为60.0%和100.0%.多因素分析提示CD117的表达和Masaoka分期是影响患者预后的独立危险因素.结论 p53、CD117和CD44v5表达可协助明确胸腺上皮肿瘤分型,尤其检测CD117和CD44v5表达可辅助鉴别诊断胸腺癌与胸腺瘤.p53和CD44v5表达可反映胸腺上皮肿瘤的侵袭性. Objective To investigate the expression of p53, CD117 and CD44v5 in thymus epithelial tumor and their correlation with clinicopathological features and prognosis of thymus epithelial tumor in combining with WHO classification and Masaoka stage. Methods The immunohistochemical expression of p53, CD117 and CD44v5 in tissues from 104 resected thymus epithelial tumors with different types and stages and 10 normal thymuses by tissue microarray. The correlation between the expression of the proteins and the clinicopathological features or prognosis was analyzed. Results Of 104 thymus epithelial tumors,38.2% were positive for p53, 15.7% positive for CD117 and 57.8% positive for CD44v5 respectively.All 10 normal thymuses were not positive for the three proteins. There was significant difference in the expression of p53, CD117 and CD44v5 p53 among WHO histological classifications ( P 〈 0. 05 ). The expression of p53 and CD44v5 showed significant difference among Masaoka stages (P 〈 0. 05). The positive expression rate of CD117 (60. 0%) and CD44v5 ( 100. 0% ) was significantly increased in thymic carcinoma. COX regression multivariate analysis indicated that the increased CD117 expression and Masaoka staging were significant independent prognostic factors. Conclusion p53, CD117 and CD44v5 are useful immunohistochemical markers for the diagnosis of thymus epithelial tumor, and the examination of CD117 and CD44v5 would greatly help in the differential diagnosis of thymic carcinoma from thymoma. The expression of p53 and CD44v5 in thymus epithelial tumor can predict its invasive capacity.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2010年第9期1215-1217,共3页 Chinese Journal of Experimental Surgery
基金 国家自然科学基金资助项目(30670823)
关键词 低流量灌注 心脏保存 心肌保护 Thymus epithelial tumor p53 CD117 CD44v5
  • 相关文献

参考文献8

  • 1Taylor DO,Edwards LB,Boucek MM,et al.Twenty-second official adult heart transplant report.Thorac Cardiovasc Surg,2005,24:945-955.
  • 2Minatoya K,Okabayashi H,Shimada I,et al.Intermittentanteg rade warm blood cardioplegia for CABG:extended interval of cardioplegia.Ann Thorac Surg,2000,69:74-76.
  • 3St-Peter SD,Imber CJ,Friend PJ.Liver and kidney preservation by perfusion.Lancet,2002,359:604-613.
  • 4Wicomb WN,Collins GM.24-hour rabbit heart storage with UW solution.Effects of low-flow perfusion,colloid,and shelf storage.Transplantation,1989,48:6-9.
  • 5范克军,朱有华,张纯,罗明.自制多器官保存液对草犬肾脏低温保存的实验研究[J].中华实验外科杂志,2003,20(3):246-247. 被引量:7
  • 6Careaga G,Salazar D,Tellez S,et al.Clinical impact of histidine-ketoglutarate-tryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients.Arch Med Res,2001,32:296-299.
  • 7李世康,龙村,程邦昌,刘唐威,何巍,陈铭伍,史世勇.组氨酸-色氨酸-酮戊二酸与威斯康星大学溶液对冠状动脉内皮细胞的影响[J].中华实验外科杂志,2003,20(4):309-310. 被引量:7
  • 8邢家林,龚庆成.康斯特保护液的心肌保护效果[J].中国体外循环杂志,2006,4(1):55-58. 被引量:11

二级参考文献12

  • 1[1]Engelman RM ,Levitsky S.A textbook of Cardioplegia for Difficult Clinical Problems[J].Mount Kisco,NY ,Futura Publishing Company,Inc,1992:203.
  • 2[2]Jakob VJ.Myocardial Protection:An Overview[J].J Extra Corpor Technol,2000,32:38 - 47.
  • 3[3]Gebhard MM,Bretschneider HJ,Gersing E,et al.Calciumfree cardioplegia[J].Euro Heart J,1983,4 (Supplement H),151 - 160.
  • 4[4]Martin J,Lutter G,Ihling C,et al.Myocardial viability twentyfour hours after orthotopic heart transplantation from non - heartbeating donor[J].J Thorac Cardiovasc Surg ,2003,125:1217.
  • 5[5]Houischer M,Groenewoud AF.Current status of the HTK solution of Bretschneider in organ preservation [J].Transplantion Proc,1991,23:2334 -2337.
  • 6[6]Nido PJ,Wilson GJ,Mickle DA,et al.The role of cardioplegic solution buffering in myocardial protection[J].J Thorac Cardiovas Surg,1985,89:689 -699.
  • 7[7]Hachida M,Ookado A,Nonoyama M,et al.Effect of HTK solution for myocardial preservation[J].J Cardiovas Surg,1996,37:269 - 274.
  • 8[8]Kjellman UW,Bjork K,Ekroth R,et al.Addition of α - Ketoglutarate to Blood Cardioplegia Improves Cardio - protection[J].Ann Thorac Surg 1997,63:1625 - 1634.
  • 9[9]Preusse C J,Gebhard MM,Bretschneider H J:Myocardial "equilibration processes" and myocardial energy turnover during initiation of artificial cardiac arrest with cardioplegic solution:Reasons for a sufficiently long cardioplegic perfusion[J].Thorac Cardiovasc Surg 1981,29:71.
  • 10[10]Sakata J,Morishita K,Ito T,et al.Comparison of Clinical Outcome Between HTK solution and Cold Blood Cardioplegic Solution in Mitral Valve Replacement[J].J Card Surg ,1998,13:43 - 47.

共引文献22

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部